^
22h
Golidocitinib Combined With GemOx in RR PTCL (clinicaltrials.gov)
P2, N=31, Not yet recruiting, Ruijin Hospital
New P2 trial
|
oxaliplatin • golidocitinib (DZD4205)
22h
New P1 trial
|
doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • daunorubicin • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
2d
Primary Cutaneous CD30-Positive Lymphoproliferative Disorder With Gamma-Delta T-Cells: A Molecular-Annotated Case With a Classic Clinical Appearance and Behavior. (PubMed, J Cutan Pathol)
Altogether, these findings were insufficient to establish a diagnosis of pcGDTCL. We review the clinical, histopathologic, and molecular sequencing data pertaining to our rare patient as well as the recent literature on indolent CD30+LPD with gamma-delta T-cells.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • TNFRSF8 (TNF Receptor Superfamily Member 8) • LRP1B (LDL Receptor Related Protein 1B) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • EPHA7 (EPH Receptor A7)
|
HER-2 mutation • TNFRSF8 positive
2d
Nodal T-follicular helper cell lymphoma with hodgkin/reed-sternberg-like cells: Clinicopathologic and molecular characterization of 11 cases. (PubMed, Pathol Res Pract)
AITL with HRS-like cells is prone to misdiagnosis as CHL due to overlapping morphological and immunophenotypic features. Integration of EBER, TCR/IG clonality assessment, and molecular profiling, particularly the identification of TET2 and RHOA mutations is essential for accurate classification. Recognizing this entity is critical for avoiding diagnostic pitfalls and guiding appropriate therapeutic strategies.
Journal • PD(L)-1 Biomarker • IO biomarker
|
DNMT3A (DNA methyltransferase 1) • PD-1 (Programmed cell death 1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • BCL6 (B-cell CLL/lymphoma 6) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2D (Lysine Methyltransferase 2D) • CREBBP (CREB binding protein) • PAX5 (Paired Box 5) • CD4 (CD4 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • ICOS (Inducible T Cell Costimulator) • RHOA (Ras homolog family member A) • MME (Membrane Metalloendopeptidase) • BRD4 (Bromodomain Containing 4)
|
TET2 mutation • TNFRSF8 positive • TNFRSF8 expression
|
CART-30
3d
Cure of a CD20-positive peripheral T-cell lymphoma-NOS with CHOPE regimen plus surgery a case report and literature review. (PubMed, Front Med (Lausanne))
In order to improve the efficacy, recent studies have confirmed that the combination of etoposide (CHOPE regimen) on the basis of CHOP regimen can significantly improve the treatment response for newly diagnosed patients aged ≤ 65 years...The patient received four cycles of CHOPE regimen after surgical resection of the primary tumor and underwent PET/CT mid-term evaluation. Through this case, we aim to further explore the pathological diagnosis difficulties of such rare cases and preliminarily evaluate the clinical application value of CHOPE regimen.
Journal
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Rituxan (rituximab) • etoposide IV
3d
DP06 Decoding histology: γδ T-cell lymphoma vs. tumour-stage mycosis fungoides. (PubMed, Br J Dermatol)
A trial of flucloxacillin produced no improvement, and an urgent ultrasound revealed nonspecific skin thickening, prompting a skin biopsy...In this case, the absence of systemic involvement on imaging and the atypical immuno-phenotypic features underscore the complexity of distinguishing between tumour-stage MF and PCGDTCL. This case highlights the role of detailed histopathological evaluation of rare cutaneous lymphomas and emphasizes the need for a multidisciplinary approach to design both local and systemic treatment strategies for individual patients.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • JAK3 (Janus Kinase 3) • CD5 (CD5 Molecule) • MAPK1 (Mitogen-activated protein kinase 1) • CD7 (CD7 Molecule) • CD2 (CD2 Molecule)
3d
P025 Primary cutaneous extranodal natural killer/T-cell lymphoma, nasal type: a case report. (PubMed, Br J Dermatol)
Treatment with gemcitabine and oxaliplatin chemotherapy showed significant improvement, complemented by radiotherapy for refractory lesions. Histopathological evaluation and EBV testing are critical for differentiation from other conditions. While initial responses to chemoradiotherapy are promising, recurrence remains common, highlighting the need for vigilant follow-up and optimized therapeutic strategies.
Journal
|
CD20 (Membrane Spanning 4-Domains A1) • PAX5 (Paired Box 5) • NCAM1 (Neural cell adhesion molecule 1) • GZMB (Granzyme B)
|
CD20 positive
|
gemcitabine • oxaliplatin
3d
New P2 trial
|
azacitidine • Xpovio (selinexor)
3d
New P2 trial
|
cyclophosphamide • thiotepa • busulfan
3d
Mice carrying nonsense mutant p53 develop frequent multicentric or metastatic tumors. (PubMed, Cell Death Dis)
Our new unique mouse model will allow further studies of the effects of Trp53 nonsense mutation in a multi-organ system and serve as a model for the Li-Fraumeni syndrome (LFS). It will also be valuable for preclinical evaluation of novel therapeutic strategies for targeting TP53 nonsense mutations in cancer.
Preclinical • Journal
|
TP53 (Tumor protein P53)
|
TP53 mutation
4d
Report of a case of nasal-type extranodal NK/T-cell lymphoma with ciliary body involvement and literature review of interleukin-10 and interleukin-6 in intraocular T-cell lymphoma. (PubMed, Am J Ophthalmol Case Rep)
The patient underwent five cycles of intravitreal methotrexate for presumed uveal lymphoma involving the ciliary body with pseudo-keratic precipitates before a nasal biopsy confirmed recurrent ENKL...The IL-10/IL-6 ratio is of limited value in the diagnosis of T-cell lymphoma affecting intraocular structures. This case highlights the critical role of UBM in identifying ciliary body involvement of intraocular malignancies.
Journal
|
IL6 (Interleukin 6) • IL10 (Interleukin 10) • IL6R (Interleukin 6 receptor)
|
methotrexate
4d
An Unusual Case of Primary Mucocutaneous Cytotoxic T-Cell Lymphoma With Epidermotropism and Phenotype Switch: Diagnostic and Molecular Insights. (PubMed, J Cutan Pathol)
Despite aggressive therapy, the patient died 21 months after diagnosis. This case delineates the importance of early biopsy, integration of molecular studies, and the urgent need for therapies to improve outcomes in this aggressive lymphoma.
Journal
|
TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • JAK2 (Janus kinase 2) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • JAK3 (Janus Kinase 3) • NCAM1 (Neural cell adhesion molecule 1) • CD5 (CD5 Molecule) • GZMB (Granzyme B) • CD7 (CD7 Molecule) • CD2 (CD2 Molecule)
|
TP53 mutation